Q1 Earnings Estimate for Adicet Bio Issued By HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Adicet Bio in a research report issued to clients and investors on Wednesday, July 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright currently has a "Strong-Buy" rating and a $4.00 target price on the stock. The consensus estimate for Adicet Bio's current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio's Q2 2026 earnings at ($0.29) EPS.

Separately, Wall Street Zen began coverage on Adicet Bio in a report on Friday, May 16th. They set a "hold" rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $6.00.

Adicet Bio Trading Down 1.2%

Shares of Adicet Bio stock traded down $0.01 on Thursday, reaching $0.76. 110,750 shares of the company were exchanged, compared to its average volume of 629,792. The company has a 50-day moving average of $0.71 and a 200 day moving average of $0.76. Adicet Bio has a one year low of $0.45 and a one year high of $1.70. The company has a market capitalization of $63.03 million, a price-to-earnings ratio of -0.59 and a beta of 1.62.

Adicet Bio (NASDAQ:ACET - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.03.

Hedge Funds Weigh In On Adicet Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Adicet Bio during the fourth quarter valued at approximately $29,000. JPMorgan Chase & Co. lifted its holdings in Adicet Bio by 87.3% in the 4th quarter. JPMorgan Chase & Co. now owns 150,485 shares of the company's stock worth $145,000 after buying an additional 70,132 shares during the period. Norges Bank purchased a new stake in Adicet Bio in the fourth quarter worth $413,000. Northern Trust Corp raised its position in shares of Adicet Bio by 25.1% in the 4th quarter. Northern Trust Corp now owns 140,369 shares of the company's stock worth $135,000 after purchasing an additional 28,153 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in Adicet Bio by 20.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 1,026,600 shares of the company's stock valued at $988,000 after acquiring an additional 175,000 shares during the period. 83.89% of the stock is owned by institutional investors and hedge funds.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.